NCE-1 Intelligence & Market Opportunity

Bylvay

Odevixibat

Hepatoprotective agents

Oral Capsule

Approval Date

20-Jul-21

NCE-1 Date

20-Jul-25

NCE Date

20-Jul-26

Commercial snapshot

Market performance & projections

Revenue ($M)

203

CAGR (%)

0.2348

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

275

2027

342

2028

408

2029

472

2030

531

2031

565

2032

572

Molecule profile

Details & specifications

Molecule

Odevixibat

Innovator

IPSEN BIOPHARMACEUTICALS, INC.

Dosage Form

Oral Capsule

Strength

1.2 mg, 0.4 mg, 0.6 mg, 0.2 mg

Therapeutic Category

Hepatoprotective agents

Usage

To treat pruritus

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.